November 14, 2014AJP Lung Cellular and Molecular Physiology
Vasculopathy and pulmonary hypertension in sickle cell disease
Authors
Discussion
Loading...
Member takes
Implication
Clinical review uncovers mechanisms of hemolysis-driven vasculopathy in sickle cell disease, highlighting clinical strategies for managing secondary pulmonary hypertension.
Key Points
- To review the molecular pathobiology of hemolysis-mediated endothelial dysfunction and outline consensus strategies for diagnosing and managing pulmonary hypertension in sickle cell disease.
- Synthesized molecular and cellular evidence detailing how erythrocyte damage-associated molecular patterns (eDAMPs), free heme, and arginase 1 drive vascular injury.
- Evaluated current diagnostic criteria, risk stratification models, and therapeutic recommendations from American Thoracic Society (ATS) consensus guidelines.
- Intravascular hemolysis releases cell-free hemoglobin and heme that scavenge nitric oxide, produce reactive oxygen species, and trigger innate immunity via toll-like receptor 4.
- Chronic vasculopathy culminates in pulmonary hypertension in approximately 10% of patients, presenting with increased pulmonary vascular resistance, reduced cardiac output, and frequent progression to fatal right heart failure.
Cite This Study
Potoka et al. (2014) studied this question.